Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients

Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients

Introduction: A growing evidence suggests that immune dysregulation and thrombotic phenomena are key features in the pathophysiology of COVID-19. Apart from antivirals and respiratory support, anticoagulants, corticoids and immunomodulators are increasingly being prescribed, especially for more seve...

Full description

Bibliographic Details
Main Authors: Buzon-Martín Luis, Montero-Baladía Miguel, Delgado-López Pedro, Iglesias-Posadilla David, Astigarraga Itziar, Galacho-Harriero Ana, Iglesias-Julián Enrique, López-Veloso María, De La Torre-Ferrera Noelia, Barraza-Bengoechea Julio César, Ubeira- Iglesias Marta, San Llorente- Sebastián Rodrigo, Colazo-Burlato María, Lorenzo-Martín Andrés, Minguito de la Iglesia Javier, García-Muñoz Juan Pablo, Hermida-Fernández Gerardo, Navarro-San Francisco Carolina, Boado-Lama Jorge, Fernández-Regueras María, Callejo-Torre Fernando, Ossa-Echeverri Sergio, Fisac-Cuadrado Lourdes, Gero-Escapa María, Megías-Lobón Gregoria, Simón-Rodríguez Adolfo, Fernández-Ratero José Antonio
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Journal of Translational Autoimmunity
Subjects:
COVID-19
Coronavirus
SARS-CoV-2
Epidemiology
Diagnosis
Treatment
Online Access:http://www.sciencedirect.com/science/article/pii/S258990902100006X

Internet

http://www.sciencedirect.com/science/article/pii/S258990902100006X

Similar Items